The Tisch Cancer Institute and Division of Hematology/Medical Oncology, The Icahn School of Medicine at Mount Sinai Hospital, New York, NY.
Blood Adv. 2018 Nov 27;2(22):3411-3417. doi: 10.1182/bloodadvances.2018020214.
Acute graft-versus-host disease (GVHD) targets the crypts in the gastrointestinal (GI) tract that are responsible for the self-renewal of the intestinal mucosa. Recent advances in the identification and culture of intestinal stem cells have improved our understanding of the interactions between the microbiome and the immune system (both innate and adaptive) that are key to the pathophysiology of GVHD. The identification of serum biomarkers that best predict long-term GVHD outcomes derive from the GI tract and have focused attention on cellular elements that act as shields against GVHD as well as its targets. These biomarkers have illuminated new mechanisms of crypt biology and provided insights that should prove useful both in the design of clinical trials and as guides to GVHD prevention and treatment.
急性移植物抗宿主病(GVHD)的靶标是胃肠道(GI)道中的隐窝,这些隐窝负责肠道黏膜的自我更新。最近在鉴定和培养肠道干细胞方面的进展提高了我们对微生物组与免疫系统(先天和适应性)之间相互作用的认识,这些相互作用是 GVHD 病理生理学的关键。能够最好地预测长期 GVHD 结局的血清生物标志物来自于胃肠道,并引起了人们对充当 GVHD 及其靶标盾牌的细胞成分的关注。这些生物标志物阐明了隐窝生物学的新机制,并提供了有价值的见解,这不仅有助于临床试验的设计,而且有助于指导 GVHD 的预防和治疗。